Aside from campaign volunteers, fewer than a dozen people showed up to listen to the candidates on a steamy Sunday afternoon.
Health Care + Med Tech
Since opening in March, the Mayo Clinic Business Accelerator has filled its offices with 16 tenants, including medical startups and venture capitalists.
Minneapolis-based Medafor, which develops medical devices used to control bleeding, is the second Twin Cities med-tech company purchased by C.R. Bard, Inc., in recent years.
The move marks a departure from Medtronic’s traditional emphasis on medical devices.
Jeff Bolton, who has served as chief financial officer of the health system since 2002, will succeed longtime Mayo executive Shirley Weis as chief administrative officer.
U.S. District Judge Joan Ericksen ruled against AGA Medical Holdings in a patent lawsuit involving a medical device used to treat heart defects.
Current state law prohibits the price of a plan from becoming public until its “effective date,” which was originally October 1 for plans included in MNsure.
Essentia Health and St. Luke's are leading Duluth employers.
GdB created “out-of-home” advertising for the campaign.
The Minnesota hearing aid maker is renovating its 122,000-square-foot facility to make room for future work force growth.
Uroplasty appointed its interim CEO, Robert Kill, to the roles of president and CEO. Chief Financial Officer Mahedi Jiwani—who was placed on leave during an internal review—has now retired.
Mark Dayton gets four appointments to the eight-member board.
Minneapolis has the ninth-most patent applications for every 10,000 metro residents in the world.
Mayo Clinic ranked third in the country, while four other Minnesota hospitals earned a “national ranking” on the recently released list.
Communications firm WCG is opening a Minneapolis office in the hopes of expanding its Midwest client base.
A “woman of influence” is defined as being active in major investment decisions, having a good understanding of financial products, and having an interest in learning about financial matters.
The company, which is focused on developing a cancer vaccine, has completed its Chapter 11 reorganization and has appointed Carlos Santos as its new CEO.
The Minneapolis-based company, which raised more than $200 million prior to the recession, said it will use the new funding to help finance clinical trials.